1. Home
  2. Products
  3. Customized ADCs
  4. TNFSF11
  5. Anti-TNFSF11 (Denosumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC

Anti-TNFSF11 (Denosumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2239)

This ADC product is comprised of an anti-TNFSF11 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • TNFSF11
  • Alternative Names
  • TNFSF11; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand superfamily member 11; CD254; ODF; OPGL; RANKL; TRANCE; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand; sOdf; OPTB2; hRANKL2;
  • Target Entrez Gene ID
  • 8600
  • Overview
  • This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
  • Overview
  • Human Anti-TNFSF11 IgG2 antibody, Denosumab
  • Generic name
  • Denosumab
  • Host animal
  • Human
  • Name
  • MC-Vc-PAB-DMEA-(PEG2)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • duocarmycin SA
  • Description
  • Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-2239. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2238 Anti-TNFSF11 (Denosumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2237 Anti-TNFSF11 (Denosumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-2235 Anti-TNFSF11 (Denosumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2236 Anti-TNFSF11 (Denosumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2234 Anti-TNFSF11 (Denosumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-2547 Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2564 Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2594 Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2570 Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2553 Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
CAT# Product Name Linker Payload
ADC-W-2564 Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2542 Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2588 Anti-EGFR (Zalutumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2594 Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2576 Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.